SCHEDULE: Pentwater Capital Discloses 5.2% Stake in Amedisys

Sentiment:

Beneficial Ownership Report


Pentwater Capital Management LP and Matthew Halbower have disclosed a passive 5.2% beneficial ownership stake in Amedisys Inc.

Summary

  • Pentwater Capital Management LP and Matthew Halbower have filed a Schedule 13G, reporting beneficial ownership of 1,715,084 shares of Amedisys Inc. Common Stock.
  • This ownership represents 5.2% of Amedisys Inc.'s outstanding Common Stock.
  • The percentage is calculated based on 32,819,638 shares of Common Stock outstanding as of April 25, 2025, as reported in Amedisys's Form 10-K/A filed on April 29, 2025.
  • The shares are held by certain Pentwater Funds, for which Pentwater Capital Management LP acts as the investment adviser and Matthew Halbower is the sole shareholder of the general partner.
  • The Reporting Persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Amedisys Inc.

Sentiment

Score: 5

Explanation: The filing is a standard beneficial ownership disclosure, indicating a passive investment. It does not contain information that would inherently suggest positive or negative sentiment regarding the issuer's performance or prospects.

Positives

  • NA

Negatives

  • NA

Risks

  • NA

Future Outlook

NA

Industry Context

This filing indicates a significant passive investment by Pentwater Capital Management LP in Amedisys Inc., a company operating in the healthcare services sector. Such disclosures are common for investment firms taking passive stakes in publicly traded companies.

Stakeholder Impact

  • Shareholders: Disclosure of a new significant passive shareholder may provide some market visibility, but typically has limited direct impact on operations or strategy.

Key Dates

DateDescription
04/25/2025Date as of which Amedisys Inc. reported 32,819,638 shares of Common Stock outstanding in its Form 10-K/A.
04/29/2025Date Amedisys Inc. filed Amendment No. 2 to its Annual Report on Form 10-K/A for the fiscal year ended December 31, 2024.
06/30/2025Date of event which required the filing of this statement.
08/14/2025Date the Schedule 13G was signed and filed by Pentwater Capital Management LP and Matthew Halbower.

Keywords

Amedisys, Pentwater Capital Management, Matthew Halbower, Beneficial Ownership, Schedule 13G, Common Stock, Healthcare Services, Investment Management

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.